Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7820671 | VERTEX PHARMS | Peptidomimetic protease inhibitors |
Feb, 2025
(1 year, 11 months from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8431615 | VERTEX PHARMS | Dose forms |
May, 2028
(5 years from now) |
Market Authorisation Date: 23 May, 2011
Treatment: Method of treating chronic hepatitis c
Dosage: TABLET;ORAL
15
United States
12
Korea, Republic of
11
European Union
9
China
8
Taiwan, Province of China
6
Japan
5
Norway
4
Germany
4
Spain
3
Hong Kong
3
Canada
3
Israel
3
Australia
2
New Zealand
2
Mexico
2
Austria
2
EA
2
Ukraine
2
Ecuador
2
Denmark
1
Portugal
1
El Salvador
1
Malaysia
1
Russia
1
Brazil
1
Croatia
1
Argentina
1
Peru
1
South Africa
1
Slovakia
1
Cyprus
1
Hungary
1
Slovenia
1
Luxembourg
1
Czech Republic
1
Poland
1
Chile
1
Algeria
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic